In Brief: Fresenius USA
This article was originally published in The Gray Sheet
Executive Summary
Fresenius USA: Dialysis equipment manufacturer plans first quarter 1998 North American roll-out of its On-Line Clearance (OLC) dialysis dose monitor for end stage renal disease patients, the company says. The device, which gained 510(k) clearance in June, can be retrofitted to the Fresenius 2008H dialysis machine and will be included on 70-80% of all new machines sold, the firm says. Unlike competing devices, the OLC immediately provides nephrologists with treatment dose information, Fresenius maintains...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.